Showing Grants 1 to 10 of 850 |
| A Developing Story: HIV Resistance Among African Populations May be Linked to Genotypic Traits of Type 2 Diabetes |
| | Elijah Songok, Kenya Medical Research Institute, Nairobi, Kenya - KE |
|
| |
| |
|
Phase I
|
Elijah Songok at the Kenya Medical Research Institute hopes to better understand preliminary findings from studies of sex workers that natural resistance to HIV may be linked to genetic markers for type 2 diabetes.
|
| A Mutable Vaccine for HIV |
| | Marilia Cascalho, University of Michigan, Ann Arbor, MI, United States - US |
|
| |
| |
|
Phase I
|
Marilia Cascalho of the University of Michigan will test whether a “mutable”DNA vaccine in which the gene coding for the antigen mutates a million times more frequently than a typical gene will trigger immune response that anticipates the production of new viral variants and produces broadly neutralizing antibodies against HIV. |
| A New Platform for Making Effective Vaccines Against Pathogens That Cause Infectious Diseases |
| | Ellen Vitetta, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, United States - US |
|
| |
| |
|
Phase I
|
Ellen Vitetta of University of Texas Southwestern Medical Center at Dallas is developing a new vaccine platform that will utilize synthetic B cell epitope mimetics (peptoids) conjugated to protein carriers to make vaccines that will induce robust, specific, and protective antibody responses against pathogens. |
| A Novel Antimicrobial Delivery System |
| | George O'Toole, Dartmouth College, Hanover, NH, United States - US |
|
| |
| |
|
Phase I
|
George O’Toole, a microbiologist at Darmouth Medical School, and Mark Grinstaff, a biomedical engineer and chemist at Boston University, will work to develop an expansile nanoparticle, packed with high concentrations of antibiotics, which would expand and release their content when internalized by host cells. The hope is that more precise delivery of high concentrations of antimicrobial agents, in single or combination therapies, will reduce the development of resistance. |
| A Novel Approach to Prevent or Cure HIV Infection |
| | Karthikeyan Kandavelou, Pondicherry Biotech Pvt Ltd, Pondicherry, India - IN |
|
| |
| |
|
Phase I
|
People born with a natural resistance to the HIV virus have a genetic mutation in the CCR5 gene. Karthikeyan Kandavelou of Pondicherry Biotech Pvt. Ltd. in India will attempt to achieve targeted disruption of CCR5 genes, making an important first step in a new strategy to make people permanently resistant to HIV. |
| A Novel Structure-Based Model for the Prediction and Exploitation of Resistance Mutations |
| | Ryan Lilien, University of Toronto, Toronto, Ontario, Canada - CA |
|
| |
| |
|
Phase I
|
Dr. Ryan Lilien of the University of Toronto in Canada will work to computationally model the structural and functional effects of point mutations on a target protein's active site. With the development of predictive models of pathogen evolution and the spread of resistance, this information can be used to guide drug development and optimization.
|
| A Targeted Stealth Weapon of Viral Destruction for HIV |
| | Karen Anderson, Yale University, New Haven, CT, United States - US |
|
| |
| |
|
Phase I
|
HIV has a very high rate of mutation allowing it to very rapidly develop resistance to AIDS therapies. The essential viral enzyme, HIV reverse transcriptase, lacks a "proofreading" or "repair activity" leading to errors or mutations. Karen Anderson of Yale University is working on "stealth" compounds that have a unique anchor specific for HIV. These compounds encourage the virus to make mutations until the virus is annihilated. |
| Alternative Strategies to Eradicate the Latent HIV-1 Reservoir |
| | Olaf Kutsch, University of Alabama, Birmingham, AL, United States - US |
|
| |
| |
|
Phase I
|
Olaf Kutsch of the University of Alabama proposes that HIV latency is controlled by host-gene promoter interference, a mechanism that prevents the initiation of viral gene expression. Understanding how host-gene promoter interference controls latent HIV-1 infection may aid development of therapies to deplete latent HIV in patients. |
| An Innovative Strategy to Induce Potent Mucosal Immune Responses Against HIV |
| | Yue Chen, University of Pittsburgh, Pittsburgh, PA, United States - US |
|
| |
| |
|
Phase I
|
Yue Chen of the University of Pittsburgh will attempt to develop an oral HIV vaccine based on Clostridium perfringens, a bacteria able to withstand upper GI conditions to deliver large amounts of antigens to gut-associated lymphoid tissue, a major site of HIV activity. |
| Anaerobic Shock as a Novel Treatment for Tuberculosis |
| | Xilin Zhao, University of Medicine and Dentistry of New Jersey, Newark, NJ, United States - US |
|
| |
| |
|
Phase I
|
Xilin Zhao of the University of Medicine and Dentistry of New Jersey will test whether anaerobic gas, which causes rapid depletion of oxygen, will kill the tuberculosis bacteria without permanent damage to surrounding tissue. |